Northrop Grumman (NOC) Stock Rallies As Q3 Earnings Reinforce Margin Gains

Northrop Grumman just dropped its Q3 2026 scorecard and the stock immediately jumped 4.6% to about US$534. The mood on the screen says relief rally. The numbers point to something more grounded in cash.

Earnings per share of roughly US$7.91 and revenue of about US$11.1b were solid, but the real story sits in profitability. Trailing net margin near 10.4% and a P/E around 16.8x against much higher industry averages frame today’s move as investors reassessing a defense contractor that has been quietly tightening its earnings engine.

Like the earnings power at Northrop Grumman but want a broader set of companies that combine solid profitability with robust balance sheets? Scan our curated screener of list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$11,122m vs US$10,423m (up about 6.7%)
• Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): US$1,124m vs US$1,100m (up about 2.2%)
• Basic EPS (Q3 2026 vs Q3 2025): US$7.91 vs US$7.69 (up about 2.9%)
• Trailing Net Profit Margin (Last 12 Months vs Prior 12 Months): 10.4% vs 9.8% (improved by 0.6 percentage points)

Ask Charlie what Northrop Grumman said about the B-21 ramp.

Northrop Grumman: Testing The Execution Upside

The bullish script says execution on big programs and capacity builds turns today’s backlog into stronger profit power.

"The main requirement for this narrative is continued execution on high visibility programs and capacity buildouts, including B-21, Sentinel, munitions and solid rocket motors, and national security space, while keeping segment margins on track despite pockets of contract pressure and elevated capital expenditure."

Q3 lands on the supportive side of that claim. Segment operating income rose faster than sales, segment margin reached 12.1%, and adjusted free cash flow of US$1.8b comfortably covered higher capex. Raised 2026 EPS and segment income guidance, with segment margin implied near 11.3%, points to these ramps translating into tangible profitability rather than just booked backlog.

Northrop Grumman: Stress Testing Execution Risk

The bear story focuses on cost blow ups on complex work that could eat into those same margins.

"Execution issues on complex fixed price contracts, as seen in the unfavorable estimate at completion adjustments on the Stand in Attack Weapon program and the GEM 63XL program, show that cost or schedule overruns can quickly compress segment margins and may weigh on company wide net margins and earnings if similar issues occur on other projects."

Recent numbers show that concern, but not this quarter’s outcome. Segment margin held above 12%, net margin over the last 12 months improved to 10.4%, and EPS increased. Guidance for 2027 still assumes modest margin expansion and higher free cash flow even with capex around 4.5% of sales, which suggests prior problem contracts remain contained for now.

One Narrative disagrees with today's price. → See where this Narrative says Northrop Grumman should trade.

Hunt For Quiet Earnings Power

Northrop Grumman just showed how steady execution can reset expectations without a dramatic headline surprise. The real opportunity is finding stocks that could be undervalued before the market closes those gaps.

• Company 1 - 25% below our estimate - sells injectable therapies for weight loss and diabetes as demand strains supply.
• Company 2 - 40% below our estimate - expands specialty deposit verticals and digital platforms so fee income grows.
• Company 3 - 47% below our estimate - converts a record backlog of technology heavy projects into higher margin work.

That is three of the list. See the full list of 34 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com